Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. - Wikidata - awgldk - TriplyDB

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

http://www.wikidata.org/entity/Q36885846

about

Molecular Targeted Therapies of Aggressive Thyroid Cancer Update: the status of clinical trials with kinase inhibitors in thyroid cancer Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma.Peroxisome proliferator-activated receptor-γ agonist troglitazone suppresses transforming growth factor-β1 signalling through miR-92b upregulation-inhibited Axl expression in human keloid fibroblasts in vitro.A new dawn for the use of thiazolidinediones in cancer therapy.Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?Antihyperglycaemic therapies and cancer risk.PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014).Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.Adiponectin and its receptor signaling: an anti-cancer therapeutic target and its implications for anti-tumor immunity.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer.Personalization of targeted therapy in advanced thyroid cancer.Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.Optimal combination of treatment modality to increase survival in patients with anaplastic thyroid carcinoma: A STROBE compliant retrospective study.

P2860

Q26774734-4D5FEAD0-1420-45EE-A8A7-F18445BB7062 Q33570056-A914DD71-B13B-4290-AAAC-B73AAC4A60E0 Q35578234-F63F2C12-8393-477F-A629-0F84660BE2B4 Q35622067-B661DEAF-885F-4AE7-83A9-08F4344E15C4 Q36027160-30D8461F-4278-48DD-9E8A-F41292262100 Q37086070-D3EBBE00-15B7-4A26-ACE1-AA5A1CA56831 Q37088201-3EE68DB8-993F-4BF7-BE5C-2CCA3ABFC9EC Q37227987-1E9433A7-739F-4007-B902-88C061FA60E5 Q38193545-D4617A7E-F0C1-4137-B144-32B911C7C5BC Q38217116-230BA34E-785D-4A6E-A363-C6FE720C81D6 Q38250719-E0B6BDE1-41ED-412C-868C-2BB25B997793 Q38270503-7392FA32-9A07-457B-B0A1-B50AFDF64C07 Q38441002-A37828E7-F719-4385-A3AE-37462541FB27 Q38465754-497C1ED7-2FDE-4566-9A1F-8EEC42945CC3 Q38657760-7E6E208A-7B35-4641-AD61-8E283DBF2105 Q38754489-6D2C86E0-B15D-4C38-8D84-A6ADF38DFFCE Q38798863-528CEDB4-411B-49AE-831B-A669D491CB9C Q38815256-59C79557-7759-4D1E-AEB9-10416AC35B83 Q38979602-07F792D4-84E3-4AB5-9E53-FCBBA750DCFC Q39082422-24F3F17A-5991-4DA1-A28B-7D6AA5DF6CD0 Q40922523-E66A8CEE-969D-4AF5-8884-9925D36A8A9B Q52638921-DCF88802-187B-427B-A8CF-327AB6CBB23F Q55406601-17C9E16F-3A09-4E08-B32A-0AF74E1AC768

P2860

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial.

http://www.wikidata.org/entity/Q36885846

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.

@en

type

label

Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.

@en

prefLabel

Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.

@en

P1433

Q36885846-5CCDE4B4-9601-4812-96F7-61F2C0307F1B

P1476

Q36885846-7E35AE23-49D9-4CFD-B52A-FC2FDA8B0354

P2093

Q36885846-1F695C94-90FA-4E90-9C46-08FD18CA8E9C

Q36885846-23289EEE-FB43-46F0-89D0-B321CA45C005

Q36885846-355EE065-ECA0-4DCD-AAF0-06C4E70FEAD9

Q36885846-3CC91AB2-61F3-4E4F-81A4-9BDE30E1D437

Q36885846-41550A41-A91F-4CE5-8E8A-0161D7719784

Q36885846-7D209CB9-1648-4D4F-B73F-6538A15BBEFE

Q36885846-7D78E3B5-1F2B-4C0A-9AB5-712F114EDEBD

Q36885846-916AC845-2029-41B3-AE1C-3CEC429C8CDE

Q36885846-9D5DB9B9-A873-4A65-9D0F-AA479D6B2220

Q36885846-AF295A06-A61A-40C2-8497-6E32D10B0C25

P2860

Q36885846-1552D11B-0C3D-4F86-80F8-0156031B180E

Q36885846-166911E8-A8FA-449D-AFD9-BC49416246C6

Q36885846-1C2B2742-5E1C-4B0C-A61E-4003539DBA2F

Q36885846-28CA9D34-0D41-40F8-99B9-F1BEB16C42D2

Q36885846-2A6C2E8D-637A-4409-AC9C-C812CF2D25BB

Q36885846-3F85751A-FBEE-452A-AB33-46A25ACBE936

Q36885846-3F8B7CF4-91BB-4415-B9D5-6065D980CE98

Q36885846-4974C7C4-5F0B-4CB4-B397-46618E819EA8

Q36885846-6C084B8F-A8C1-419E-937D-78100AABB4A3

Q36885846-85094722-716C-4715-B9C0-16FDE36ED1AE

P304

Q36885846-6DBF245B-E9D5-4D1C-8941-CB8E5F356889

P31

Q36885846-368EB56A-477B-47B6-BAA5-EC07F3211C3B

P356

Q36885846-457E28F7-B0A6-43B0-9910-4FABFB33D33C

P407

Q36885846-E2FB73C9-2BFF-45C8-BEE9-FDDE8C7E6066

P433

Q36885846-E155A79F-0CF7-43FD-B4FC-E60CDD28E1EC

P478

Q36885846-CCDF22C7-EE95-43D0-A2FB-9DF98DA734E5

P577

Q36885846-08E65B98-4851-42E6-A1F8-70F4C10BE3FC

P698

Q36885846-CFC10E4F-7A86-4471-9529-77F2FEB872EF

P921

Q36885846-536797A4-8424-4027-8610-726BD8915F7A

Q36885846-FA977F12-22BC-41E3-9319-ECFCD9B45AF0

P932

Q36885846-EDCD1B95-1977-4AA5-BE5C-64ADF3102D7D

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Efatutazone, an oral PPAR-γ ag ...... f a multicenter phase 1 trial.

@en

P2093

A W Gramza

http://www.w3.org/2001/XMLSchema#string

J A Copland

http://www.w3.org/2001/XMLSchema#string

J P Klopper

http://www.w3.org/2001/XMLSchema#string

J T Wadsworth

http://www.w3.org/2001/XMLSchema#string

K C Bible

http://www.w3.org/2001/XMLSchema#string

L A Marlow

http://www.w3.org/2001/XMLSchema#string

M E Menefee

http://www.w3.org/2001/XMLSchema#string

M G Heckman

http://www.w3.org/2001/XMLSchema#string

M H Shah

http://www.w3.org/2001/XMLSchema#string

M S Brose

http://www.w3.org/2001/XMLSchema#string

P2860

Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth

Cancer statistics, 2012

Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells

Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators.

Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

P304

2392-2400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2013-1106

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23589525

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

multicenter trial

P932

3667260

http://www.w3.org/2001/XMLSchema#string